Abstract
Considerable effort has been made to develop drugs that delay or prevent neurodegeneration. These include inhibitors of Aβ-generating proteases for the treatment of Alzheimers disease. Testing the amyloid hypothesis in vivo requires molecules that are capable of entering the CNS and that produce a substantial reduction in brain Aβ levels. Plaque-developing APP transgenic mice are currently widely used as an in vivo model of choice as these animals produce readily measurable amounts of human Aβ. They are very useful in the testing of a variety of amyloid-lowering approaches but their use for compound screening is often limited by their cost. Transgenic animals also require extensive, timeconsuming breeding programs and can show high inter-animal differences in the expression level of the transgene. Hence, we considered it important to develop and characterize a new and simple non-transgenic animal model for testing Aβ modulation. For this purpose, Wild-type adult Sprague Dawley rats were treated with DAPT, a functional γ-secretase inhibitor, and the Aβ40 and Aβ42 levels in brain-tissue and body fluids were assessed. We showed that DAPT, given orally, significantly lowered Aβ40 and Aβ42 peptide levels in brain extract, CSF, and the plasma dose- and timedependently. We can conclude that our data establish the usefulness of the wild-type rat model for testing small-molecule inhibitors of Aβ production.
Keywords: BACE1 inhibitors, ELISA, Monoclonal antibody, presenilin 1 (PS1), APP transgenic mice
Current Pharmaceutical Design
Title: Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Volume: 12 Issue: 6
Author(s): Mohammed El Mouedden, Marc Vandermeeren, Theo Meert and Marc Mercken
Affiliation:
Keywords: BACE1 inhibitors, ELISA, Monoclonal antibody, presenilin 1 (PS1), APP transgenic mice
Abstract: Considerable effort has been made to develop drugs that delay or prevent neurodegeneration. These include inhibitors of Aβ-generating proteases for the treatment of Alzheimers disease. Testing the amyloid hypothesis in vivo requires molecules that are capable of entering the CNS and that produce a substantial reduction in brain Aβ levels. Plaque-developing APP transgenic mice are currently widely used as an in vivo model of choice as these animals produce readily measurable amounts of human Aβ. They are very useful in the testing of a variety of amyloid-lowering approaches but their use for compound screening is often limited by their cost. Transgenic animals also require extensive, timeconsuming breeding programs and can show high inter-animal differences in the expression level of the transgene. Hence, we considered it important to develop and characterize a new and simple non-transgenic animal model for testing Aβ modulation. For this purpose, Wild-type adult Sprague Dawley rats were treated with DAPT, a functional γ-secretase inhibitor, and the Aβ40 and Aβ42 levels in brain-tissue and body fluids were assessed. We showed that DAPT, given orally, significantly lowered Aβ40 and Aβ42 peptide levels in brain extract, CSF, and the plasma dose- and timedependently. We can conclude that our data establish the usefulness of the wild-type rat model for testing small-molecule inhibitors of Aβ production.
Export Options
About this article
Cite this article as:
Mouedden El Mohammed, Vandermeeren Marc, Meert Theo and Mercken Marc, Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors, Current Pharmaceutical Design 2006; 12 (6) . https://dx.doi.org/10.2174/138161206775474233
DOI https://dx.doi.org/10.2174/138161206775474233 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Current Pharmaceutical Design Age-related Changes in Respiratory Function and Daily Living. A Tentative Model Including Psychosocial Variables, Respiratory Diseases and Cognition
Current Aging Science Mobilization and Redistribution of Default Mode Network from Resting State to Task State in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Current Drug Targets for Modulating Alzheimer's Amyloid Precursor Protein: Role of Specific Micro-RNA Species
Current Medicinal Chemistry Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard?
Current Drug Safety Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Development and Evaluation of a Tactile Cognitive Function Test Device for Alzheimer’s Disease Early Detection
Neuroscience and Biomedical Engineering (Discontinued) Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of Therapeutic Strategy)
Current Pharmaceutical Design Amyloid-β in the Cerebrospinal Fluid of APP Transgenic Mice Does not Show Prion-like Properties
Current Alzheimer Research The Effects of Aerobic Exercise on Cognitive Function of Alzheimer's Disease Patients
CNS & Neurological Disorders - Drug Targets New Insights on the Beneficial Effects of the Probiotic Kefir on Vascular Dysfunction in Cardiovascular and Neurodegenerative Diseases
Current Pharmaceutical Design The Estrogenic Burden on Vascular Risk in Male-to-Female Transsexuals
Current Pharmaceutical Design The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Heme Oxygenase-1 Dysregulation in the Brain: Implications for HIVAssociated Neurocognitive Disorders
Current HIV Research The Impact of Marijuana Use on Memory in HIV-Infected Patients: A Comprehensive Review of the HIV and Marijuana Literatures
Current Drug Abuse Reviews